中文
| Catalogue |
|
|
| Recommend Products |
Sygnature Discovery Limited.
United Kingdom, Manufacturer, Hits: 1417, Updated:11/9/2018
BioCity, Pennyfoot Street, Nottingham NG1 1GR, United Kingdom |
Company Profile
-
Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services company. Private equity-backed since 2017, we operate fully-enabled research facilities in Nottingham and Alderley Park, UK, housing over 200 research scientists (80% with PhDs). Our experienced drug hunters possess all of the professional skills and know-how required to undertake the most demanding of research programmes and drive them from target validation through hit identification, hit-to-lead and lead optimisation to pre-clinical development candidate. Since 2011, we have delivered 14 drug candidates to our clients which have subsequently entered the clinic (Phases I and II). In 2017, Sygnature Discovery received the prestigious Queen’s Award for Enterprise for International Trade.
Company News
- Sygnature Discovery Appoints Dr Charles Woler as Chairman 1/14/2022
- New CFO Jordison Steps up at Sygnature Discovery 12/1/2021
- Sygnature Discovery Expands into Early CMC Development 6/17/2021
- Sygnature Discovery Appoints Dr. David Lustig to Spearhead US Expansion 5/7/2021
- Sygnature Discovery Expands US Presence with Office in Bay Area Biotech Hub 4/28/2021
- Sygnature Discovery Creates 2nd Integrated Drug Discovery Site At Alderley Park 2/19/2021
- Sygnature Discovery Invests ￡3m to Expand High-throughput Screening and Translational Oncology Cap... 12/17/2020
- Sygnature Discovery Expands DMPK Capabilities with Acquisition of XenoGesis 9/25/2020
- Sygnature Discovery and RenaSci Strengthen Drug Abuse Leadership with Appointment of Dr Andy Mead 9/10/2020
- Sygnature Discovery Boosts Senior Management Team with Appointment of Dr Paul Overton 6/24/2020